AZTA
Azenta, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 15 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Feb 16
- Mar 3 ▲ Gilbert Cisneros bought $1,001 - $15,000, last disclosed Apr 8
- Apr 7 Azenta announced a leadership transition in its Multiomics division,…
- May 5 ▼ Azenta reported Q2 FY2026 revenue of $145M (+1% reported, -3% organi…
- May 18 ▲ 1 insider buy $163.8K at $16.38
- Jul 31 ▲ 1 insider buy $8.1K at $24.17
- Aug 4 ▲ Azenta (AZTA) reported Q3 fiscal 2026 results with non-GAAP EPS of $…
- Oct 30 M&A: Azenta Announces Strategic Investments to Advance the Next…
- Nov 10 ▲ Earnings: AZTA Q4 2026 Earnings: EPS $0.28 (+153.6% vs est)
- Nov 10 ▲ Azenta reported Q4 FY2026 revenue of $167M (+5% YoY, +2% organic), s…
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $171.9K at an average $16.63. No open-market sales. Price is 184% above their cost.
- InstitutionsMIXED
Q3 2026: 28 added (1 new), 19 trimmed or exited. Largest new: Renaissance Technologies $10.1M.
- AnalystsBULLISH
8 of 12 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $0.140 → $0.114 over 90 days. 0 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +0.8% to 5.40M shares. 6.2 days to cover, ≈12.3% of shares.
- TrendUPTREND
28% above its 50-day average. New closing high $48.90 on Nov 11.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JUPITER ASSET MANAGEMENT LTD | ADD | $22.9M |
| Allspring Global Investments Holdings, LLC | TRIM | $20.2M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | $17.4M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | TRIM | $16.6M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $13.5M |
| JPMORGAN CHASE & CO | ADD | $13.1M |
| RENAISSANCE TECHNOLOGIES LLC | NEW | $10.1M |
| MARSHALL WACE, LLP | DOUBLED | $9.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +10%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Jefferies MAINTAIN | Buy |
| Nov 11, 2026 | Needham MAINTAIN | Buy |
| Sep 14, 2026 | Needham REITERATE | Buy |
| Aug 6, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Aug 5, 2026 | Needham MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 16, 2026 | TAX W/H | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | TAX W/H | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | AWARD | |
| 🔒 Fresh data, subscribers only Nov 16, 2026 | TAX W/H | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | AWARD | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | AWARD | |
| 🔒 Fresh data, subscribers only Nov 12, 2026 | AWARD | |
Madaus Martin D Interim CEO Oct 22, 2026 | TAX W/H | $46.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.11 | $0.05–$0.15 | -8.8% | $158.5M |
| Next Q | $0.11 | $0.09–$0.17 | -31.4% | $156.4M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 1 press release · 2 bullish · 2 bearish · 2 mixed · 5 neutral- BULLISH 8-KNov 10, 2026
Azenta reported Q4 FY2026 revenue of $167M (+5% YoY, +2% organic), slightly above the $160.2M…
The FY2027 guidance for 3-5% organic growth and 200-250 bps margin expansion, plus the recent Elegen/SynPlexity investments, indicate management expects a return to profitable growth. Monitor Q1…
- NEUTRAL 8-KOct 30, 2026
Azenta announced two strategic transactions to expand its GENEWIZ gene synthesis capabilities: an…
Monitor Azenta's Q4 FY2026 earnings call for additional details on the financial impact and integration timeline. The $25M perpetual license option decision between 12-18 months from October 2026 is…
- NEUTRAL PRESS RELEASEOct 30, 2026
Azenta announced an exclusive licensing agreement with Elegen Corp. for cell-free DNA synthesis…
Monitor the Q4 fiscal 2026 earnings call for deal financials and integration milestones. The lack of disclosed terms limits near-term valuation impact; focus on any revenue guidance or margin…
- BEARISH 8-KOct 7, 2026
Azenta announced a restructuring plan within its Multiomics segment, involving workforce…
The restructuring is the third cost-cutting action in FY2026, with the Multiomics segment bearing the brunt. Monitor the Q1 FY2027 10-Q for actual charge amounts and whether the $11M savings target…
All AZTA filing & press-release reports (12)
- 8-K reportNov 10, 2026
- 8-K reportOct 30, 2026
- PRESS-RELEASE reportOct 30, 2026
- 8-K reportOct 7, 2026
- 8-K reportSep 17, 2026
- 8-K reportSep 4, 2026
- 8-K reportAug 24, 2026
- INST-CLUSTER reportAug 8, 2026
- PRESS-RELEASE reportAug 4, 2026
- 8-K reportJul 8, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 7, 2026